CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Ther Adv Med Oncol
; 12: 1758835920952994, 2020.
Article
in En
| MEDLINE
| ID: mdl-33193825
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Ther Adv Med Oncol
Year:
2020
Document type:
Article
Affiliation country:
Italia
Country of publication:
Reino Unido